| Industry
The development of clinical breakpoints for new agents requires agreement and acceptance of the data generated in support of decisions on clinical breakpoints, wild type MIC distributions, ECOFFs and routine susceptibility testing correlates.
EUCAST and CLSI both favour the use of the unadulterated ISO recommended reference broth microdilution for this purpose, and only occasionally is there good reason to deviate from this. When this is considered necessary it is strongly advised that this is with the agreement and full understanding of standards committees and agencies, such as CLSI, EUCAST, FDA and EMA. For this purpose EUCAST has published:
For previous version of documents visit EUCAST SOPs.
| Industry
| Industry
Looking for more information? Get in touch with an EUCAST representative today!
We’ve prepared a short video to help you get familiar with the new layout and features.